Hemophilia A - Pipeline Review, H2 2019

December 2019 | 212 pages | ID: H909533E405EN
Global Markets Direct

Abstracts

Hemophilia A - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides an overview of the Hemophilia A (Hematology ) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematology ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematology ) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A (Factor VIII Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 16, 8, 3, 1, 29, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Hemophilia A (Hematology ) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematology ).
• The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematology ) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hemophilia A (Hematology ) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hemophilia A (Hematology ) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematology )

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematology ).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematology ) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hemophilia A (Factor VIII Deficiency) - Overview
Hemophilia A (Factor VIII Deficiency) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hemophilia A (Factor VIII Deficiency) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemophilia A (Factor VIII Deficiency) - Companies Involved in Therapeutics Development
Alveron Pharma
ApcinteX Ltd
Apitope International NV
ASC Therapeutics Inc
Ascension Healthcare Plc
Beijing Northland Biotech Co Ltd
Beijing Tiantan Biological Products Co Ltd
BioMarin Pharmaceutical Inc
Cabaletta Bio Inc
Casebia Therapeutics
Catalyst Biosciences Inc
Chugai Pharmaceutical Co Ltd
CSL Ltd
Daiichi Sankyo Co Ltd
DBV Technologies SA
Dnarx LLC
EpiVax Inc
Expression Therapeutics LLC
Freeline Therapeutics Ltd
GC Pharma
Generation Bio Corp
Genzyme Corp
ID Pharma Co Ltd
Idogen AB
Immusoft Corp
Innovare R & D SA De CV
Kaifeng Pharmaceutical (Group) Co Ltd
Kymab Ltd
LambdaGen Therapeutics
LFB SA
NovalGen Ltd
Novo Nordisk AS
Octapharma AG
OPKO Biologics Ltd
Pangen Biotech Inc
Pfizer Inc
Pharming Group NV
Precision Biosciences Inc
ProFactor Pharma Ltd
Recursion Pharmaceuticals Inc
Sangamo Therapeutics Inc
Sanofi
Serpinx BV
Shenzhen Weiwu Guangming Biological Preparations Co Ltd
Sigilon Therapeutics Inc
Sino Biopharmaceutical Ltd
Sinocelltech Ltd
Spark Therapeutics Inc
Takeda Pharmaceutical Co Ltd
TeraImmune Inc
Ultragenyx Pharmaceutical Inc
UniQure NV
XL-protein GmbH
Hemophilia A (Factor VIII Deficiency) - Drug Profiles
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hemophilia A (Factor VIII Deficiency) - Pipeline by Alveron Pharma, H2 2019
Hemophilia A (Factor VIII Deficiency) - Pipeline by ApcinteX Ltd, H2 2019
Hemophilia A (Factor VIII Deficiency) - Pipeline by Apitope International NV, H2 2019
Hemophilia A (Factor VIII Deficiency) - Pipeline by ASC Therapeutics Inc, H2 2019
Hemophilia A (Factor VIII Deficiency) - Pipeline by Ascension Healthcare Plc, H2 2019
Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019
Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019
Hemophilia A (Factor VIII Deficiency) - Dormant Projects, H2 2019 (Contd..2), H2 2019
Hemophilia A (Factor VIII Deficiency) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019